Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2017.04.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of 1 mcg/mL as the starting dose in cluster protocol for hymenoptera immunotherapy.
Allergol Immunopathol (Madr)
January 2025
Department of Allergy and Clinical Immunology, Firooz Abadi Hospital, Iran University of Medical Sciences, Tehran, Iran;
Background: Hymenoptera venom allergy is a potentially severe allergic reaction in the general population. The only preventative approach in these cases is venom immunotherapy (VIT), which follows different protocols. The recommended initial dose is 0.
View Article and Find Full Text PDFEvaluating Practice Patterns of Observation Periods Following Epinephrine Administration for Anaphylaxis Among Pediatric Patients.
Cureus
September 2024
Department of Pediatric Emergency Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, USA.
Article Synopsis
- - Current guidelines suggest observing anaphylactic patients for 4-6 hours after receiving epinephrine, but there's conflicting evidence about its effectiveness, especially for children.
- - This study looked at pediatric patients treated for anaphylaxis in a single ED from 2017-2022 to see how often biphasic reactions occurred and if the observation periods were adequate.
- - Out of 292 patients observed for an average of about 233 minutes, only 3.4% developed biphasic reactions, with no significant differences found in observation duration or timing of epinephrine administration between those who did and did not experience these reactions.
Long term safety and efficacy of ligelizumab in the treatment of Japanese patients with chronic spontaneous urticaria.
Allergol Int
January 2025
Novartis Pharma AG, Basel, Switzerland.
Article Synopsis
- In Japan, a study was conducted on the safety and efficacy of ligelizumab, an anti-IgE monoclonal antibody, for treating chronic spontaneous urticaria (CSU) in patients who weren't responding well to H1-antihistamines.
- The study, which included 66 adult participants, showed that while 80.3% experienced mild to moderate side effects, there were no severe adverse events or anaphylaxis, and only 6.1% stopped treatment due to side effects.
- Significant improvements were noted: UAS7 scores improved quickly by Week 4 and continued to improve by Week 52, with 50% of patients achieving no symptoms, and a notable increase in quality of life
Kounis Syndrome: A Case Report and a Review of Recent Literature.
Cureus
July 2024
Interventional Cardiology, King Abdulaziz Medical City, Riyadh, SAU.
Kounis syndrome (KS) is commonly defined as acute myocardial infarction (AMI) secondary to exposure to an allergen. There are multiple identified allergens that are associated with KS, examples include medications, food, and contrast media. After exposure to an allergen, the allergic pathway is triggered leading to vasospasm in coronary vessels which later on presents as AMI.
View Article and Find Full Text PDFMedical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting.
Intern Emerg Med
September 2024
Dipartimento Area Emergenza-Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
During COVID-19 pandemic, vaccination has been strongly recommended and advocated to prevent COVID-19 infection and adverse outcomes, particularly among at-risk populations. The vaccination against SARS-CoV-2 (COVAC) occurred at off-site locations capable of accommodating large crowds, distinct from the hospital setting, where a team of intensivists, emergency physicians, and nurses, ensuring prompt medical attention (medical occurrences, MO) in cases of adverse event following immunization. Our aims were to estimate the incidence of MO, and to assess its association with demographics, and vaccine characteristics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!